Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 5/20 | 0.49 |
| ▸ | MEP1B | Q16820 | 3/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | PPM1D | O15297 | 1/20 | 0.46 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30444177 | 0.90 | KDM1A (0.54) | KDM1AMEP1BFOLH1PPM1DMRGPRX4 | |
| SCHEMBL21088517 | 0.86 | PPM1D (0.57) | KDM1AMEP1BFOLH1PPM1DHIF1A | |
| SCHEMBL30443983 | 0.86 | KDM1A (0.51) | KDM1AMEP1BFOLH1PPM1DMRGPRX4 | |
| SCHEMBL15820177 | 0.85 | LOXL2 (0.52) | PRMT5KDM1APPM1DPRKD1MRGPRX4 | |
| SCHEMBL791813 | 0.83 | THRB (0.51) | KDM1AMEP1BFOLH1PPM1DMRGPRX4 | |
| SCHEMBL16355841 | 0.81 | SLC7A5 (0.48) | PRMT5KDM1APRKD1MRGPRX4PDCD1 | |
| SCHEMBL375264 | 0.78 | GRIN2B (0.62) | — | |
| SCHEMBL23684547 | 0.78 | GRIK1 (0.51) | FOLH1PPM1DMRGPRX4HIF1AKMO | |
| SCHEMBL17308302 | 0.77 | ALDH1A1 (0.49) | PRMT5PRKD1PDCD1CD274 | |
| SCHEMBL382597 | 0.77 | MAP4K4 (0.46) | PRMT5PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20210308121-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2021-10-07 | — | — | US | disclosed |
| US-10980794-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190343826-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-11-14 | — | — | US | disclosed |
| US-10391089-B2 | PRMT5 inhibitors and uses therof | Epizyme, Inc. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180098987-A1 | PRMT5 Inhibitors and Uses Thereof | Epizyme, Inc. (US) | 2018-04-12 | — | — | US | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9675614-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9604930-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170027935-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-02-02 | — | — | US | disclosed |
| US-9199927-B2 | Guanidinobenzoic acid compound | ASTELLAS PHARMA INC. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-25 | — | — | US | disclosed |
| WO-2014100719-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210308121-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885KDM1A 34/4885MEP1B 253/4885 |
| US-20190343826-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885KDM1A 47/4885MEP1B 322/4885 |
| US-20180098987-A1 | PRMT5 Inhibitors and Uses Thereof | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885KDM1A 34/4885MEP1B 253/4885 |
| US-10391089-B2 | PRMT5 inhibitors and uses therof | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885KDM1A 78/4885MEP1B 955/4885 |
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885KDM1A 47/4885MEP1B 322/4885 |
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | SERPINB1, REN, SPINT2 | PRMT5 1187/4885KDM1A 2425/4885MEP1B 412/4885 |
| US-20170027935-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885KDM1A 34/4885MEP1B 253/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885KDM1A 47/4885MEP1B 322/4885 |
| US-10980794-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885KDM1A 34/4885MEP1B 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.